158 results on '"Li, D"'
Search Results
2. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
3. 1036P A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
4. High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
5. Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case–Control Consortium (PanC4)
6. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes
7. 1736P An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS).
8. 578P Increased therapeutic index of muzastotug (ADG126), a masked anti-CTLA-4 antibody, in combination with pembrolizumab (pembro) enables significant clinical benefits and supports further clinical development in patients with metastatic MSS CRC.
9. 92P Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
10. 841P Effects of immune checkpoint inhibitor-based combination therapies on the gut microbiota in advanced melanoma patients
11. 1707P The landscape of PALB2 alteration in Chinese solid tumor patients
12. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
13. LBA38 Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)
14. 1117P Intratumoral microbiota is associated with prognosis in Chinese patients with skin melanoma
15. 983P Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
16. 724P Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
17. The age-dependent association of risk factors with pancreatic cancer
18. P-124 Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments: Balancing overall survival and quality of life
19. P-77 A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma
20. PD-7 Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study
21. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4)
22. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)
23. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)
24. 781P Efficacy and safety of apatinib combined with chemotherapy in patients of cervical cancer with pulmonary metastasis
25. P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress
26. 1991P Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
27. 1198P Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
28. 1012P First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
29. 977P Hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib and PD-1 inhibitors versus Regorafenib combined with PD-1 inhibitors for second-line treatment Hepatocellular carcinoma (HCC)
30. 896P Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
31. 95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
32. Reply to the letter to the editor ‘The link between type 2 diabetes and pancreatic adenocarcinoma is yet to be established’ by Rahman and Meeran
33. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4)
34. Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?
35. 169P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
36. 265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
37. LBA88 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
38. 1404P Immune microenvironment could be responsible for response to immune checkpoint inhibitors among NSCLC patients with various EGFR mutation types
39. 1920P Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk
40. 1114P A real-world study of vemurafenib plus anti-PD-1 antibody in Chinese patients with advanced BRAF V600-mutant melanoma
41. 1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
42. 1227P Comprehensive molecular characterization of Chinese patients with early stage multiple primary lung cancer
43. O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150
44. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
45. Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
46. Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
47. Safety and tolerability of surufatinib in western patients with solid tumours
48. Clinical and molecular characteristics of ALK-rearranged Chinese lung cancer patients
49. A real world study of apatinib treatment in gastric cancer: Current status and clinical benefit
50. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.